OPAMTISTOMIG
UNII K3DDY28BJF

Substance Identification & Data

This profile provides standardized clinical and technical data for Opamtistomig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) K3DDY28BJF.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2923499-76-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

K3DDY28BJF

CAS Registry Number

2923499-76-5

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

OPAMTISTOMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C216002

National Cancer Institute reference terminology for clinical and research data.

INN ID

13330

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Opamtistomig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Opamtistomig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Opamtistomig

Common Names & Synonyms

H-gamma1 heavy chain anti-CD274 fused to a scFvhl anti-TNFRSF9 (1-714) [H-gamma1 heavy chain anti-CD274 humanized (1-449) [VH (Homo sapiens IGHV4-30-4*09 (87.8%) -(IGHD) -IGHJ4*01 (93.3%) L123>T (114), CDRIMGT [8.7.13] (26-33.51-57.96-108)) (1-119)-Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, 6-G1v14-4 CH2 A1.3, A1.2, A114, 1-G1v66 CH2 A27 (CH1 K120 (216) (120-217), hinge 1-15 (218-232), CH2 L1.3>A (236), L1.2>A (237), D27>A (267), P114>A (331) (233-342), CH3 D12 (358), L14 (360) (343-447), CHS (448-449)) (120-449)] -15-mer tris(tetraglycyl-seryl) linker (450-464) -scFvhl anti-TNFRSF9 Homo sapiens (465-714), C49 (VH)-C120 (VL) 11-scFv-v1 [VH (Homo sapiens IGHV3-30*01 (92.9%) -IGHD -IGHJ6*03 (95.0%) G49>C (508), CDR-IMGT [8.8.17] (490-497.515-522.561-577)) (465-588) -15-mer tris(glycyl-tetraseryl) linker (589-603) -V-LAMBDA (Homo sapiens IGLV2-14*01 (91.9%) -IGLJ7*01 (90.9%) G120>C (707), CDR-IMGT [9.3.11] (629-637.655-657.694-704)) (604-714)]]; (222-214')-disulfide with L-kappa light chain anti-CD274 humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-16*01 (84.2%) -IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153'), V101 (191') (108'-214')]; dimer (228-228'':231-231'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa

Immunoglobulin G1 [236-alanine,237-alanine,267-alanine,331-alanine], anti-(human/Macaca fascicularis programmed death-ligand PD-L1) (human-Mus musculus monoclonal HUL02 γ1-chain) fusion protein with peptide linker ((GGGGS)3) fusion protein with immunoglobulin anti-(human/Macaca fascicularis tumor necrosis factor receptor TNFRSF9) (human monoclonal 41BB-2 single-chain variable region fragment VH-(GSSSS)3-VL), disulfide with human-Mus musculus monoclonal HUL02 κ-chain, dimer

immunoglobulin (H-gamma1-scFvhl_L-kappa) dimer, anti-[Homo sapiens CD274 (programmed cell death 1 ligand 1, PDL1, PD-L1, B7 homolog 1, B7H1, B7-H1, PDCD1LG1)] and anti-[Homo sapiens TNFRSF9 (TNF receptor superfamily member 9, 4-1BB, T cell antigen ILA, CD137)], humanized and Homo sapiens monoclonal antibody, tetravalent, bispecific (opamtistomig)

opamtistomig [INN]

External Clinical & Regulatory Resources

Previous UNIIK3D9A0ICQ3

Next UNIIK3E0U7O8KI